Open access
Open access
Powered by Google Translator Translator

Interventional Cardiology

Analysis | An easy way to spot bias in observational studies

31 Jan, 2023 | 14:02h | UTC

An Easy Way to Spot Bias in Observational Studies – Sensible Medicine

 

Commentary on Twitter

 

M-A | Transcatheter versus surgical aortic valve replacement in lower-risk and higher-risk patients

31 Jan, 2023 | 13:59h | UTC

Transcatheter versus surgical aortic valve replacement in lower-risk and higher-risk patients: a meta-analysis of randomized trials – European Heart Journal (free for a limited period)

 

Commentary on Twitter

 

Review | Mitral valve transcatheter edge-to-edge repair

31 Jan, 2023 | 13:40h | UTC

Mitral valve transcatheter edge-to-edge repair – EuroIntervention

 

Commentary on Twitter

 

2023 Guidelines on the diagnosis and management of chronic coronary syndrome

25 Jan, 2023 | 11:25h | UTC

2023 Guidelines of the Taiwan Society of Cardiology on the Diagnosis and Management of Chronic Coronary Syndrome – Acta Cardiologica Sinica

Related: 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology

 

Left heart catheterization complications | ED presentations, evaluation, and management

9 Jan, 2023 | 14:07h | UTC

Left Heart Catheterization Complications: ED Presentations, Evaluation, and Management – emDocs

 

Consensus Statement | Radiation protection for healthcare professionals working in catheterization laboratories during pregnancy.

9 Dec, 2022 | 13:26h | UTC

Radiation protection for healthcare professionals working in catheterisation laboratories during pregnancy: a statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) in collaboration with the European Heart Rhythm Association (EHRA), the European Association of Cardiovascular Imaging (EACVI), the ESC Regulatory Affairs Committee and Women as One – EuroIntervention

Commentary: Expert Consensus Advocates for Normalizing Pregnancy in Cath Labs – TCTMD

 

Commentary on Twitter

 

M-A | Bioresorbable scaffolds vs. drug-eluting stents for patients with myocardial infarction.

22 Nov, 2022 | 13:29h | UTC

Bioresorbable scaffolds vs. drug-eluting stents for patients with myocardial infarction: A systematic review and meta-analysis of randomized clinical trials – Frontiers in Cardiovascular Medicine 

Related: M-A | Bioresorbable vascular scaffolds are inferior compared to conventional drug-eluting stents across time. 

 

RCT | Bivalirudin is superior to heparin in patients with ST-segment elevation myocardial infarction undergoing primary PCI.

15 Nov, 2022 | 13:00h | UTC

Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial – The Lancet

Commentaries:

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI – TCTMD

Bivalirudin found to be safer and more effective than heparin for treating heart attack patients undergoing percutaneous coronary intervention – Mount Sinai School of Medicine

BivaliRudin with prolonged full-dose Infusion during primary PCI versus Heparin Trial – BRIGHT-4 – American College of Cardiology

 

M-A | Bioresorbable vascular scaffolds are inferior compared to conventional drug-eluting stents across time.

10 Nov, 2022 | 13:57h | UTC

Bioresorbable vascular scaffolds versus conventional drug-eluting stents across time: a meta-analysis of randomised controlled trials – openheart

 

Commentary on Twitter

 

M-A | Safety and efficacy of interrupting dual antiplatelet therapy one month following percutaneous coronary intervention.

1 Nov, 2022 | 12:14h | UTC

Safety and efficacy of interrupting dual antiplatelet therapy one month following percutaneous coronary intervention: a meta-analysis of randomized controlled trials – BMC Cardiovascular Disorders

 

Commentary on Twitter

Under a http://creativecommons.org/licenses/by/4.0/ license

 

M-A | Coronary perforation incidence, outcomes and temporal trends.

24 Oct, 2022 | 14:10h | UTC

Coronary perforation incidence, outcomes and temporal trends (COPIT): a systematic review and meta-analysis – openheart

 

M-A | The optimal timing for non-culprit PCI in patients with multivessel coronary artery disease.

21 Oct, 2022 | 12:52h | UTC

The optimal timing for non-culprit percutaneous coronary intervention in patients with multivessel coronary artery disease: A pairwise and network meta-analysis of randomized trials – Frontiers in Cardiovascular Medicine

 

Cohort Study | 3-year outcomes of patients with spontaneous coronary artery dissection.

19 Oct, 2022 | 14:23h | UTC

Canadian Spontaneous Coronary Artery Dissection Cohort Study: 3-Year Outcomes – Journal of the American College of Cardiology (link to abstract – $ for full-text)

Editorial: Spontaneous Coronary Artery Dissection: Lower Than Expected Recurrence Rate in a Large Prospective Canadian Cohort – Journal of the American College of Cardiology

Commentary: SCAD Heart Attacks: Outcomes Not as Bad as Previously Feared – Daytonews

 

Cohort Study | Incidence, predictors and clinical implications of new renal impairment following percutaneous coronary intervention.

13 Oct, 2022 | 13:42h | UTC

Incidence, predictors and clinical implications of new renal impairment following percutaneous coronary intervention – openheart

 

Commentary on Twitter

 

Review | Therapeutic management of anomalous coronary arteries originating from the opposite sinus of Valsalva.

11 Oct, 2022 | 13:32h | UTC

Therapeutic Management of Anomalous Coronary Arteries Originating From the Opposite Sinus of Valsalva: Current Evidence, Proposed Approach, and the Unknowing – Journal of the American Heart Association

 

Commentary from the author on Twitter

Under a Creative Commons Attribution‐NonCommercial License

 

RCT | Abbreviated antiplatelet therapy after coronary stenting in patients with myocardial infarction at high bleeding risk.

29 Sep, 2022 | 13:32h | UTC

Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk – Journal of the American College of Cardiology

Original publication: #ESCCongress – RCT: In patients who underwent PCI at high bleeding risk, 1 month of dual antiplatelet therapy was noninferior to the continuation of dual therapy for at least 2 additional months and resulted in a lower incidence of bleeding events.

 

ESVS Clinical practice guidelines on radiation safety.

28 Sep, 2022 | 13:46h | UTC

European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Radiation Safety – European Journal of Vascular and Endovascular Surgery

 

RCT | Routine pressure wire assessment vs. conventional angiography in patients with coronary artery disease.

27 Sep, 2022 | 13:19h | UTC

Routine Pressure Wire Assessment Versus Conventional Angiography in the Management of Patients With Coronary Artery Disease: The RIPCORD 2 Trial – Circulation

Related:

RCT: In patients with multivessel coronary artery disease, a Fractional Flow Reserve (FFR) guided revascularization strategy did not reduce the risk of ischemic cardiovascular events or death at 1-year follow-up compared to a traditional strategy without FFR.

RCT: In patients with three-vessel coronary artery disease, an FFR–guided PCI strategy was NOT noninferior to coronary bypass surgery – The 1-year incidence of the composite primary end point (death, myocardial infarction, or stroke) was 7.3% in the FFR-guided PCI group and 5.2% in the CABG group.

#ACC21 – RCT: In patients with STEMI undergoing complete revascularization, an FFR-guided strategy did not improve outcomes compared to an angiography-guided strategy.

 

Cohort Study | Incidence and outcomes of coronary artery perforations.

27 Sep, 2022 | 13:09h | UTC

Coronary Artery Perforations: Glasgow Natural History Study of Covered Stent Coronary Interventions (GNOCCI) Study – Journal of the American Heart Association

 

Secondary analysis of a RCT | Complete revascularization vs. culprit lesion–only PCI for angina-related quality of life in patients with STEMI.

22 Sep, 2022 | 13:17h | UTC

Complete Revascularization vs Culprit Lesion–Only Percutaneous Coronary Intervention for Angina-Related Quality of Life in Patients With ST-Segment Elevation Myocardial Infarction: Results From the COMPLETE Randomized Clinical Trial – JAMA Cardiology (link to abstract – $ for full-text)

Original Study: #ESCCongress – Randomized Trial: Complete Revascularization Superior to Culprit-lesion-only PCI in Patients with ST-segment Elevation Myocardial Infarction (STEMI) and Multivessel Coronary Artery Disease

Related meta-analysis:

Meta-analysis: multivessel versus culprit-only revascularization in STEMI and multivessel coronary artery disease

Meta-Analysis: Complete vs. Culprit-Lesion-Only Revascularization for ST-Segment Elevation Myocardial Infarction

Study: Nonculprit-lesion PCI Timing in Patients With ST-Segment Elevation Myocardial Infarction

Studies in patients with cardiogenic shock:

PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock – New England Journal of Medicine

One-Year Outcomes after PCI Strategies in Cardiogenic Shock – New England Journal of Medicine

 

RCT | Effect of clinical decision support with audit and feedback on prevention of acute kidney injury in patients undergoing coronary angiography.

22 Sep, 2022 | 13:04h | UTC

Effect of Clinical Decision Support With Audit and Feedback on Prevention of Acute Kidney Injury in Patients Undergoing Coronary Angiography: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)

Commentary: Intervention Cuts Risk for AKI After Coronary Angiography – HealthDay

 

Commentary on Twitter

 

RCT | Routine ultrasonography guidance for femoral vascular access for cardiac procedures improved first-pass success but did not reduce complications.

22 Sep, 2022 | 13:01h | UTC

Routine Ultrasonography Guidance for Femoral Vascular Access for Cardiac Procedures: The UNIVERSAL Randomized Clinical Trial – JAMA Cardiology (free for a limited period)

Commentary: Fluoroscopic Guidance for Femoral Artery Access—Pushing Patients Out of the Plane Without a Parachute? – JAMA Cardiology

 

Long-term follow-up of a RCT | Percutaneous coronary intervention vs. bypass surgery for multivessel coronary artery disease.

20 Sep, 2022 | 13:34h | UTC

Everolimus-Eluting Stents or Bypass Surgery for Multivessel Coronary Artery Disease: Extended Follow-up Outcomes of Multicenter Randomized Controlled BEST Trial – Circulation

Commentary: 10-Year Data From BEST Trial Find No Significant Safety or MACE Differences Between PCI With EES Versus CABG – Cardiac Interventions Today

Original Study: Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease – New England Journal of Medicine

 

RCT | Cerebral embolic protection during transcatheter aortic-valve replacement did not significantly reduce the incidence of periprocedural stroke.

19 Sep, 2022 | 12:49h | UTC

Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries:

PROTECTED TAVR: No Less Stroke With Embolic Protection, but Some See Hope – TCTMD

Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement – PROTECTED TAVR – American College of Cardiology

Presumed Clinical Benefits of TAVR Cerebral Protection Remain Unproven — Large trial comes up short in proving a definitive benefit to debris filters – MedPage Today (free registration required)

News Release: Cerebral Embolic Protection During Transcatheter Aortic-Valve Replacement – Cedars-Sinai

 

Commentary on Twitter

 

Review / Perspective | Which patients with aortic stenosis should be referred to surgery rather than transcatheter aortic valve implantation?

13 Sep, 2022 | 13:18h | UTC

Which patients with aortic stenosis should be referred to surgery rather than transcatheter aortic valve implantation? – European Heart Journal

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.